|
| 1. |
Hurst, R., Hook, B., Slater, M.R., Hatrnett, J., Storts, D.R., and Nath, N.
(2009)
Protein-protein interaction studies on protein arrays: effect of detection strategies on signal-to-background ratios.
Anal Biochem.
392
,
45-53
.
|
| |
Notes:
These authors compared 6 different detection strategies for protein-protein interactions on protein arrays. They expressed HaloTag® labeled bait proteins in a cell-free expression system, and captured these bait proteins onto coated glass slides using the HaloLink™ Array System. They then compared detection strategies using prey proteins labeled as follows: 1)35S methionine, 2) fluorescence (BODIPY-FL) and 3) biotin labeling of lysine residues using modified Lys tRNA, 4) chemical labeling after expression, 5) HaloTag® fusion, and 6) N-terminal FLAG tag. The authors evaluated signal:background ratios, adaptability to high-throughput screening, and ease of use.
(0003999) |
| |
 |
| |
Products: FluoroTect™ GreenLys in vitro Translation Labeling System | HaloLink™ Array (TNT® SP6 Wheat Germ) Two Slide System | HaloTag® Biotin Ligand | HaloTag® TMR Ligand | pF1A T7 Flexi® Vector | pFN19K HaloTag® T7 SP6 Flexi® Vector | TNT® SP6 Quick Coupled Transcription/Translation System, Trial Size | Transcend™ tRNA |
| 2. |
Wu, Y., Connors, D., Barber, L., Jayachandra, S., Hanumegowda, U.M. and Adams, S.P.
(2009)
Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds
Toxicology in Vitro
23
,
1170-1171
.
|
| |
Notes:
The authors describe a multiplexed in vitro assay to detect nephrotoxicity and gain information about mechanism of cell death in HK-2 (human kidney-2) cells. The multiplexed assay involved an LDH assay to detect necrosis, a caspase-3/7 assay to detect apoptosis, a reazurin assay to assess metabolic state, and a DNA dye staining assay to monitor nuclear morphology.
(0004002) |
| |
|
| |
Products: Caspase-Glo® 3/7 Assay | Caspase-Glo® 3/7 Buffer | Caspase-Glo® 3/7 Substrate | CellTiter-Blue® Cell Viability Assay | CellTiter-Glo® Buffer | CellTiter-Glo® Luminescent Cell Viability Assay | CellTiter-Glo® Substrate (lyophilized) | CytoTox-ONE™ Homogeneous Membrane Integrity Assay | CytoTox-ONE™ Homogeneous Membrane Integrity Assay, HTP |
| 3. |
Niles, A.L., Moravec, R.A. and Riss, T.L.
(2009)
In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high-throughput screening
Current Chemical Genomics
3
,
33-41
.
|
| |
Notes:
The authors review the use of in vitro cytotoxicity testing in drug discovery to characterize the toxic potential of new chemical entities (nce) at the earliest stages of profiling. DOI: 10.2174/1875397300903010033
(0004000) |
| |
|
| |
Products: Apo-ONE® Homogeneous Caspase-3/7 Assay | Apo-ONE® Homogeneous Caspase-3/7 Buffer | Caspase-Glo® 3/7 Assay | CellTiter-Blue® Cell Viability Assay | CellTiter-Fluor™ Cell Viability Assay | CellTiter-Glo® Assay Custom Solution | CellTiter-Glo® Luminescent Cell Viability Assay | MultiTox-Fluor Multiplex Cytotoxicity Assay | MultiTox-Glo Multiplex Cytotoxicity Assay |
| 4. |
Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A. and Lander, E.S.
(2009)
Identification of selective inhibitors of cancer stem by high-throughput screening.
Cell
138
,
645-59
.
|
| |
Notes:
The authors of this study describe a proof-of-concept screen to use mammary epithelial cells that have been induced to undergo an epithelial to mesenchymal transition (EMT) as model cells to identify agents that may be selectively toxic against "epithelial cancer stem cells" (CSCs). They induced the transformed breast cancer cell line HMLER to undergo a mesenchymal transition using shRNA directed against the E-cadherin gene. They characterized the responsiveness of these transitioned cells to common cytotoxic agents using the CellTiter® 96 AQueous Cytoxicity Assay and compared the response to that of HMLER cells containing a control shRNA. They showed that the HMLER cells induced to undergo EMT behaved more like CSCs. The researchers then performed a proof-of-concept high-throughput screen to identify compounds that targeted the HMLER cells induced to undergo EMT, using the CellTiter-Glo® Assay to assess cell viability.
(0004006) |
| |
|
| |
Products: CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay | CellTiter-Glo® Assay Custom Solution | CellTiter-Glo® Buffer | CellTiter-Glo® Luminescent Cell Viability Assay | CellTiter-Glo® Substrate (lyophilized) |
| 5. |
Xia, M., Huang, R., Guo, V., Southall, N., Cho, M.H., Inglese, J., Austin, C.P. and Nirenberg, M.
(2009)
Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory.
Proc. Natl. Acad. Sci. U S A
106
,
2412–7
.
|
| |
Notes:
In this study, small molecule enhancers of cAMP response element binding (CREB) were studied using quantitative high-throughput screening. After an initial screen of 73,000 compounds, 1,800 compounds were classified as potentiators of CREB activity. A second screening to confirm the compound potential was performed using the GloResponse™ CRE-luc2P HEK293 Cell Line. Five microliters of cells in assay medium were seeded in 1,536-well plates at a density of 2,500 cells/well. The next day, 23 nl of compound in DMSO or DMSO alone was dispensed into each well, then 1 μl of NKH477 (final concentration, 200 nM) or media alone was added to the assay plates. After incubating the cells for 4 hours at 37 °C, 6 μl of Bright-Glo™ Luciferase Assay Reagent was added to each well, incubated at room temperature for 10 minutes and the luminescence measured.
(0004004) |
| |
|
| |
Products: Bright-Glo™ Luciferase Assay System | GloResponse™ CRE-luc2P HEK293 Cell Line |
| 6. |
Hawes, J.J., Nerva, J.D. and Reily, K.M.
(2008)
Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds
J. Biolmol. Scr.
13
,
795-803
.
|
| |
Notes:
The authors of this paper created a mouse model for in vitro assays to screen for therapeutic compounds specifically active against astrocytic gliomas. A Green/Red luciferase (G/R-luc) dual-reporter system was created in KR158 cells (derived from grade III agressive mouse anaplastic astrocytoma). The green click beetle luciferase gene (from pCBC68-Basic Vector) was placed under the control of the E2F1 promoter, and the red click beetle luciferase gene (from pCBR-Basic Vector) was placed under the control of the CMV promoter. The dual-reporter assay simultaneously evaluates E2F1 promoter activity and assesses cytotocity; the assay also distinguishes cytostatic from cytotoxic compounds.
(0003949) |
| |
|
| |
Products: Chroma-Glo™ Luciferase Assay System | pCBG68-Basic Vector | pCBR-Basic Vector |
| 7. |
Cali, J.J., Niles, A., Valley, M.P., O’Brien, M.A., Riss, T.L., and Shultz, J.
(2008)
Bioluminescent assays for ADMET
Expert Opin. Drug Metab. Toxicol.
4
,
103–120
.
|
| |
Notes:
The authors of this review article highlight the use of bioluminescence as a readout for high-throughput ADME/Tox assays. They discuss three strategies for designing bioluminescent assays, using either luciferase, ATP or luciferin substrates as the limiting reagents for a luciferase-catalyzed reaction. Reporter gene assays limit the production of luciferase by tying it to a promoter or DNA regulatory region of interest. Such assays can be used to study genes that are regulated by drugs and other xenobiotics. Bioluminescent assays in which ATP is the limiting reagent of the luciferase reaction can be designed to monitor cell viability or the activity kinases. Bioluminescent assays in which the substrate is limiting can be designed so that the activity of a particular enzyme results in the production of a luciferin substrate that can, in turn, be acted upon by luciferase.
(0003926) |
| |
|
| |
Products: Apo-ONE® Homogeneous Caspase-3/7 Assay | Apo-ONE® Homogeneous Caspase-3/7 Buffer | Beta-Glo® Assay System | Calpain-Glo™ Protease Assay | Caspase-Glo® 2 Assay | Caspase-Glo® 3/7 Assay | Caspase-Glo® 6 Assay | Caspase-Glo® 8 Assay | Caspase-Glo® 9 Assay | CellTiter-Glo® Luminescent Cell Viability Assay | GloResponse™ CRE-luc2P HEK293 Cell Line | GloResponse™ NFAT-RE-luc2P HEK293 Cell Line | GSH-Glo™ Glutathione Assay | Kinase-Glo® Luminescent Kinase Assay | Kinase-Glo® Max Luminescent Kinase Assay | Kinas |
| 8. |
Schröter, T., Minond, D., Weiser, A., Dao, C., Habel, J., Spicer, T., Chase, P., Baillargeon, P., Scampavia, L., Schürer, S., Chung, C., Mader, C., Southern, M., Tsinoremas, N., Lograsso, P. and Hodder, P.
(2008)
Comparison of minaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-Kinase II (ROCK-II).
J. Biomol. Screen.
13
,
17-28
.
|
| |
Notes:
The authors of this paper compared time-resolved, fluorescence energy transfer and ATP-based luminescent assays in ultrahigh-throughput screens (1536-well) for Rho-associated kinase II inhibitors. They found that both technologies are suitable for such a screen and perform similarly; however, they note that the ATP-based luminescent kinase assay provides an economical advantage.
(0003932) |
| |
|
| |
Products: Kinase-Glo® Luminescent Kinase Assay |
| 9. |
Wierenga, K.J., Lai, K., Buchwald, P. and Tang, M.
(2008)
High-throughput screening for human galactokinase inhibitors.
J. Biomol. Screen.
13
,
415-423
.
|
| |
Notes:
Thees authors searched for small-molecule inhibitors of galactokinase (GALK). They developed an HTS assay using the Kinase-Glo® Assay System. The HTS assay used 15 μM ATP and α-D-galactose as the substrate and was performed in 384-well plates against 50,000 small molecules. Two hundred compounds were identified from the primary screen as GALK inhibitors.
(0003934) |
| |
|
| |
Products: Kinase-Glo® Luminescent Kinase Assay |
| 10. |
Hahn, C.K., Ross, K.N., Warrington, I.M., Mazitschek, R., Kanegai, C.M., Wright, R.D., Kung, A.L., Golub, T.R. and Stegmaier, K.
(2008)
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
Proc. Natl. Acad. Sci. USA
105
,
9751-9756
.
|
| |
Notes:
The authors designed a high-throughput gene-expression screen to identify compounds that induce a neuroblastoma gene signature in BE(2)-C cells. The screen used Valproic Acid (VPA), an inhibitor of histone deacetylase, as an enhancer. The top hit from the screen was all-trans retinoic acid (ATRA). The authors proposed that ATRA + VPA would reduce cell viability and might induce apoptosis by inducing genes associated with terminal differentiation. They used the CellTiter-Glo® Luminescent Cell Viability Assay in a 96-well format to assess the effects of ATRA and a variety of inhibitors of histone deacetylase on BE(2)-C cell viability.
(0003931) |
| |
|
| |
Products: CellTiter-Glo® Luminescent Cell Viability Assay |
| 11. |
Lin, H., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., Halenbeck, R., Wu, G., Zhou, A., Behrens, D., Hollenboguh, D., Linnemann, T., Qin, M., Wong, J., Chu, K., Doberstein, S.K. and Williams, L.T.
(2008)
Discovery of a cytokine and its receptor by functional screening of the extracellular proteome.
Science
320
,
807-11
.
|
| |
Notes:
The authors of this study created a cDNA library representative of the extracellular proteome (secreted proteins and the extracellular domains of transmembrane proteins). Each cDNA was individually transfected into 293T cells. Medium from the cDNA of each transfection was used in a suite of cell-based assays. The CellTiter-Glo® Assay was used to screen for secreted factors from the cell lines expressing the cDNA that affected viability of twelve cell lines: human primary B cells, human primary T cells, human primary NK cells, human primary monocytes, A549 cells, Colo205 cells, U-118 cells, MDA-MB231 cells, PC3 cells, PANC1 cells, human primary skeletal muscle progenitor cells, and rat primary oligodendrocyte precursor cells.
(0003935) |
| |
|
| |
Products: CellTiter-Glo® Luminescent Cell Viability Assay |
| 12. |
Kawaguchi, T., Chen, Y.P., Norman, R.S. and Deecho, A.W.
(2008)
Rapid screening of quorum-sensing signal N-acyl homoserine lactones by an in vitro cell-free assay.
Appl. Environ. Microbiol.
74
,
3667-3671
.
|
| |
Notes:
The authors of this paper describe the development of a cell-free assay system derived from Agrobacterium tumefaciens NTL4(pCF218) (pCF372), which expresses β-galactosidase under the control of a tra1 promoter. The tra1 promoter is responsive to quorum-sensing signals. The assay was developed to address time-consuming cell conditioning and incubation times of the standard whole-cell assays used to detect quorum-sensing signals in natural systems. Replacing the X-Gal substrate with the luminescent Beta-Glo® substrate increased the assay sensitivity by tenfold.
(0003936) |
| |
|
| |
Products: Beta-Glo® Assay System |
| 13. |
Davis, R. E., Zhang, Y-Q., Suthall, N., Staudt, L.M., Austin, C.P., Inglese, J. and Auld, D.S.
(2007)
A cell-based assay for IκBα stabilization using a two-color dual luciferase-based sensor
ASSAY and Drug Development Technologies
5
,
85-103
.
|
| |
Notes:
The Chroma-Luc™ vectors, which encode red light-emitting and green-light emitting beetle luciferases, were used to develop an HTS cell-sensor assay (1536-well format) to detect IκBα stabilization. The assay was able to identify specific stabilizers of IκBα. Known and novel inhibitors of NFκB signaling were detected in the assay.
(0003727) |
| |
|
| |
Products: Chroma-Glo™ Luciferase Assay System | pCBG68-Basic Vector | pCBG68-Control Vector | pCBG99-Basic Vector | pCBG99-Control Vector | pCBR-Basic Vector | pCBR-Control Vector |
| 14. |
Niles, A.L., Moravec, R.A., Hesselberth, P.E., Scurria, M.A., Daily, W.J. and Riss, T.L.
(2007)
A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers
Anal. Biochem.
366
,
197–206
.
|
| |
Notes:
The authors of this paper describe an assay that uses protease biomarkers to assess cell viability and cell death simultaneously in a population of cells. The assay detects an ubiquitous protease activity that is associated with live cells and a second protease activity that is associated with cells that have lost membrane integrity. The readouts are either fluorescent or fluorescent and luminescent. The assay can be performed in multiplex with other assays, such as caspase assays, to gain additional information on the cell population, and it is amenable to high-throughput screening.
(0003927) |
| |
|
| |
Products: CytoTox-Glo™ Cytotoxicity Assay | MultiTox-Fluor Multiplex Cytotoxicity Assay | MultiTox-Glo Multiplex Cytotoxicity Assay |
| 15. |
Munagala, N., Nguyen, S., Lam, W., Lee, J., Joly, A., McMillan, K., and Zhang, W.
(2007)
Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay.
Assay and Drug Development Technologies
5
,
65-73
.
|
| |
Notes:
The authors developed a high-throughput assay in a 1536-well format using the Kinase-Glo® Luminescent Kinase Assay to test for small-molecule ceramide kinase (CERK) inhibitors. The assay was performed using a final compound concentration of 10µM, and an ATP concentration of 5µM in a total volume of 5µl. The assay was robust with Z´-factors of 0.54.
(0003590) |
| |
|
| |
Products: Kinase-Glo® Luminescent Kinase Assay |
| 16. |
Baki, A., Bielik, A., Molnár, L., Szendrei, G., and Keserü, G.M.
(2007)
A high throughput luminescent assay for glycogen synthase kinase-3β inhibitors.
Assay and Drug Development Technologies
5
,
75-83
.
|
| |
Notes:
These authors used the Kinase-Glo® Luminescent Kinase Assay to perform a high-throughput screening assay for inhibitors of glycogen synthase kinase-3β in 96-well plates. They used a 1µM ATP concentration and screened 55,000 compounds at 10µM. The assay sensitivity and IC50 values of reference compounds were comparable to radioactive methods; the final optimized assay had an average Z´-factor of 0.72.
(0003591) |
| |
|
| |
Products: Kinase-Glo® Luminescent Kinase Assay |
| 17. |
Lynch, R.A., Etchin, J., Battle, T.E. and Frank, D.A.
(2007)
A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-γ in human cancer cells
Cancer Res.
67
,
1254-1261
.
|
| |
Notes:
STAT1 is a transcription factor that is involved in a variety of cellular processes and behaves like a tumor suppressor in many ways. It is associated with apoptosis, inhibition of cyclin-dependent kinases, and it may mediate the antitumor effects of IFN-γ. The authors of this study designed a bioluminescent reporter assay to identify small molecules that enhance STAT1-dependent gene expression. The bioluminescent assay was performed in 384-well plates using both stably and transiently transfected cell lines. The screening assay was robust, producing a Z´factor value of 0.92, and it identified three compounds that specifically enhanced STAT1-dependent transcriptional activity. Firefly luciferase activity in stable cell lines was assessed using the Bright-Glo® Luciferase Assay System; luciferase activity in the transiently transfected cells was monitored using the Dual-Luciferase® Assay System. Viability of cells in culture was monitored using the CellTiter-Glo® Assay.
(0003732) |
| |
|
| |
Products: Bright-Glo™ Luciferase Assay System | CellTiter-Glo® Luminescent Cell Viability Assay | Dual-Luciferase® Reporter Assay System | pRL-TK Vector |
| 18. |
Fan, F. and Wood, K.V.
(2007)
Bioluminescent assays for high-throughput screening
Assay Drug Dev. Technol.
5
,
127–136
.
|
| |
Notes:
The authors of this paper review bioluminescent assay technologies, discussing HTS reporter, cell-based and luciferase biosensor assays. They divide luminescent assays into three basic categories: assays that measure ATP concentration (cell viability and kinase assays), assays that measure changes in luciferase levels (reporter assays, GPCR assays), and assays that measure changes in luciferin levels (protease [including caspase], P450 and MAO assays).
(0003737) |
| |
|
| |
Products: Renilla Luciferase Assay System | BacTiter-Glo™ Microbial Cell Viability Assay | Bright-Glo™ Luciferase Assay System | Calpain-Glo™ Protease Assay | cAMP-Glo™ Assay | Caspase-Glo® 2 Assay | Caspase-Glo® 3/7 Assay | Caspase-Glo® 6 Assay | Caspase-Glo® 8 Assay | Caspase-Glo® 9 Assay | CellTiter-Glo® Luminescent Cell Viability Assay | Dual-Glo® Luciferase Assay System | Dual-Luciferase® Reporter 1000 Assay System | Dual-Luciferase® Reporter Assay System | Dual-Luciferase® Reporter Assay System 10-Pack | Kinase-Glo® Lumine |
| 19. |
Rossi, C., Padmanaban, D., Ni, J., Yeh, L-A., Glicksman, M.A. and Waldner, H.
(2007)
Identifying druglike inhibitors of myelin-reactive T cells by phenotypic high-throughput screening of a small-molecule library.
J. Biomol. Screen.
12
,
481–489
.
|
| |
Notes:
The authors of this study sought to identify inhibitors of myelin-reactive T-cell proliferation. They used spleen cells isolated from transgenic mice expressing T-cell receptors that specifically recognize myelin proteolipid protein residues 139-151 (PLP139-151). Spleen cell suspensions were prepared from the transgenic mice and exposed to PLP in the presence of test compounds. Proliferation was assessed relative to positive and negative controls using the CellTiter-Glo® Luminescent Cell Viability Assay. Of the 41,184 compounds screened, 302 hits were obtained. These 302 compounds were next evaluated for nonspecific cytotoxicity using the CytoTox-ONE™ Homogeneous Membrane Integrity Assay, and compounds causing nonspecific toxicity were eliminated from further consideration. Z´-factor values for the primary screen were robust (> 0.5).
(0003733) |
| |
|
| |
Products: CellTiter-Glo® Luminescent Cell Viability Assay | CytoTox-ONE™ Homogeneous Membrane Integrity Assay | CytoTox-ONE™ Homogeneous Membrane Integrity Assay, HTP |
| 20. |
Severson, W.E., Shindo, N., Sosa, M., Fletcher, T., White, L., Ananthan, S. and Jonsson, C.B.
(2007)
Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,0000-compound library.
J. Biomol. Screen.
12
,
33
.
|
| |
Notes:
The authors of this paper describe the validation of a bioluminescent assay using the CellTiter-Glo® Reagent to identify novel compounds that inhibit the cytopathic effect of SARS CoV. In this study, three cell viability assay reagents were evaluated: MTS, neutral red, and CellTiter-Glo® Reagent. The CellTiter-Glo®-based assay was chosen because it did not require washing or medium removal; it involved minimal pipetting steps and had a short incubation time, which reduced time in the BSL3 containment facility. The assay was used to screen 100,000 compounds and identified several compounds that inhibited CPE while having a minimal effect on cell viability.
(0003736) |
| |
|
| |
Products: CellTiter-Glo® Luminescent Cell Viability Assay |
| 21. |
Kumar, M., Hsiao, K., Vidugiriene, J. and Goueli, S.A.
(2007)
A bioluminescent-based, HTS-compatible assay to monitor G-protein-coupled receptor modulation of cellular cyclic AMP
ASSAY and Drug Development Technologies
5
,
237–245
.
|
| |
Notes:
The authors of this paper introduce a luminescent assay to monitor changes in cellular cAMP concentration. The assay can be used to study the activity of G-protein coupled receptors that modulate adenylate cyclase activity. The assay is compatible with high-throughput screening in 96-, 384- and 1536-well formats.
(0003928) |
| |
|
| |
Products: cAMP-Glo™ Assay |
| 22. |
Borawski, J., Lindeman, A., Buxton, F., Labow, M. and Gaither, L.A.
(2007)
Optimization procedure for small interfering RNA transfection in a 384-well format.
J. Biomol. Screen.
12
,
546–559
.
|
| |
Notes:
A lentiviral expression vector containing the firefly luciferase gene from a pGL3 Vector was transduced into SKOV3 cells in 384-well plates, transfected with various siRNAs and analyzed 72 hours later. The luciferase expression was determined using the Bright-Glo™ Luciferase Assay System and cell viability assessed using the CellTiter-Glo® Luminescent Cell Viability Assay.
(0003729) |
| |
|
| |
Products: Bright-Glo™ Luciferase Assay System | CellTiter-Glo® Luminescent Cell Viability Assay |
| 23. |
Galkin, A.V., Melnick, J.S., Kim, S., Hood, T.L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., Wan, Y., Ding, P., Liu, Y., Sun, F., Schultz, P.G., Gray, N.S. and Warmuth, M.
(2007)
Identification of NVP-TAE684, a potent, selective and efficacious inhibitor of NPM-ALK
Proc. Natl. Acad. Sci. USA
104
,
270-275
.
|
| |
Notes:
NVP-TAE684 was identified as an inhibitor of the constitutive anaplastic lymphoma kinase (ALK) activity associated with the NPM-ALK fusion. NPM-ALK fusion protein is created by translocation event characteristic of anaplastic large-cell lymophomas. NVP-TAE684 was screened against a panel of 35 Ba/F3 cell lines expressing a variety of tyrosine kinases constitutively activated by fusion to TEL. The CellTiter-Glo® Luminescent Cell Viability Assay was used to detect any decrease in viability as a result of treatment with NVP-TAE684. The inhibitory effect of NVP-TAE684 was specific for ALK-associated cell proliferation. In a secondary screen to determine potency, TAE684 was screened against two human anaplastic large-cell lymphoma cell lines. Inhibition of proliferation correlated with dosage and was assessed using the Bright-Glo® Luciferase Assay System.
(0003738) |
| |
|
| |
Products: Bright-Glo™ Luciferase Assay System | CellTiter-Glo® Luminescent Cell Viability Assay |
| 24. |
Junker, L.M. and Clardy, J.
(2007)
High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development.
Antimicrobial Agents Chemotherapy
51
,
3582-3590
.
|
| |
Notes:
The authors of this study describe a novel bioluminescent HTS screen using the BacTiter-Glo™ Assay to identify inhibitors of biofilm formation. They compare the BacTiter-Glo™ Assay to conventional crystal violet staining and show that it produces higher Z´-factor values, is less messy and provides results over a greater range of bacterial OD. They used the BacTiter-Glo™ Assay to screen more than 60,000 compounds in 384-well plates, and identified 30 compounds representing six structural classes that inhibited biofilm formation.
(0003735) |
| |
|
| |
Products: BacTiter-Glo™ Microbial Cell Viability Assay |
| 25. |
Ji, C., Zhang, J., Cammack, N. and Sankuratri, S.
(2006)
Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression.
J. Biomol. Screen.
11
,
65–74
.
|
| |
Notes:
The effector cells of a high-throughput cell-cell fusion assay were dispensed in 384-well plates and expression of the envelope gene induced. Small-molecule compounds or antibodies being tested for their ability to prevent cell fusion were added to the effector cells (carrying firefly luciferase under control of HIV-2 LTR) prior to adding the target cells. The cells were cocultured for 20–24 hours, and luciferase expression was measured using the Steady-Glo® Luciferase Assay System.
(0003731) |
| |
|
| |
Products: Steady-Glo® Luciferase Assay System |